- In January 2024, Lupin received approval from the United States Food and Drug Administration (USFDA) to market its generic version of Propranolol Hydrochloride extended-release capsules. The approval covers various strengths of the drug, used to treat hypertension, providing an affordable alternative to the brand-name drug for managing high blood pressure in the U.S. market
- In September 2023, Pharmascience Inc. launched a new generic hypertension treatment, pms-PERINDROPIL-INDAPAMIDE, in Canada. This drug combines two active ingredients, Perindopril and Indapamide, and is prescribed to manage high blood pressure. The launch provides Canadian patients with a cost-effective option for hypertension treatment, contributing to the growing generic drug market in the country
- In July 2023, F. Hoffmann-La Roche Ltd entered into a significant agreement with Alnylam Pharmaceuticals Inc., valued at approximately USD 2.8 billion. This deal is aimed at developing a potential treatment for hypertension, marking a strategic move to expand Roche's cardiovascular portfolio. The collaboration focuses on leveraging RNA interference technology for innovative treatments
- In March 2023, Alembic Pharmaceuticals Limited received FDA approval for its Prazosin Hydrochloride Capsules, a generic version of Pfizer’s Minipress. This approval allows Alembic to market the 1 mg, 2 mg, and 5 mg strengths of Prazosin, a medication used to treat hypertension and symptoms of enlarged prostate, contributing to more affordable treatment options for patients
- In January 2023, AstraZeneca's acquisition of CinCor Pharma, focused on treating uncontrolled and resistant hypertension, strengthens its pipeline. CinCor is developing baxdrostat (CIN-107), a promising drug for treatment-resistant hypertension, and this acquisition aligns with AstraZeneca’s goal to enhance its cardiovascular portfolio. The move is expected to drive innovation in hypertension therapies
- In April 2021, Zydus Worldwide DMCC received FDA approval for Macitentan Tablets, 10 mg, a treatment for pulmonary arterial hypertension (PAH). The drug reduces the risk of disease progression and is used to manage symptoms of PAH, improving the quality of life for patients. The approval expands Zydus's presence in the cardiovascular treatment market
